Pharmaceutical Industry discussion, review, analysis, news and information.

Ingenuity Systems, Inc. (5138514) has sealed a multi-year agreement with Merck (NYSE: MRK). With the said agreement, Merck can extend and expand its access to Ingenuity Pathways Analysis (IPA) software.

Ingenuity Pathways Analysis is a software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research.

IPA is deployed in all major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally.

It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology and pharmacogenomics.

Find more details from the press release.